China has sharply restricted investigator-initiated biotech clinical trials after patient deaths, slowing what had been a surge of controversial studies. The change leaves rare disease families with fewer trial options and creates uncertainty for US investors exposed to China’s biotech sector. It matters because tighter oversight may improve safety but could also delay access and complicate cross-border investment.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
The FDA has accepted a biologics license application for a Huntington’s disease gene therapy for review, signaling another regulatory milestone for gene therapy in a difficult-to-treat neurological disease. The weekly update also notes new FDA potency guidance for cell and gene therapy manufacturers and MHRA approval of a Casgevy extension for younger patients. For professionals, these developments matter because potency expectations can affect manufacturing and review, while the label extension broadens access to an approved cell therapy.
Hundreds of thousands of doctors are turning to AI chatbots for help with care decisions, prompting health systems to weigh new risks to patient health data. Organizations now face a choice: block the tools or formally adopt them. The decision matters because it will shape how clinical AI use is governed and how sensitive patient information is protected.
A webinar will feature two experts explaining how ultra-sensitive, multiplexed proteomics can measure the pace of biological aging and assess interventions designed to change it. The discussion matters because reliable proteomic measures could help track aging trajectories and evaluate whether candidate treatments are having an effect.
India has proposed rules that would require regulators to immediately suspend manufacturing licenses when government testing shows a drug fails quality standards. For industry professionals, the move signals tighter enforcement and higher compliance risk for manufacturers, with potential implications for supply continuity and quality assurance.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
A sickle cell gene-editing therapy that had been in development for a decade was abruptly halted three years ago after the first treated patient experienced a serious adverse event. The program now appears to have a chance at revival. For professionals in gene therapy and hematology, the development is notable because it could reopen a once-abandoned editing approach for a disease with limited curative options.
New tumor cases have been reported in patients treated with AAV-based gene therapies such as Zolgensma, indicating that the widely used delivery tool may carry an oncogenic risk. The findings raise concerns for SMA patients and for gene therapy researchers assessing long-term safety. Because AAV vectors underpin many gene therapy programs, the reports could affect risk-benefit evaluations and safety monitoring across the field.
An oral therapy for obstructive sleep apnea that targets multiple pathways is positioned to add to existing treatment choices. It is expected to improve patient compliance and may lead to better outcomes, though the excerpt does not specify trial results or regulatory status.
Novartis has confirmed nine cases of tumors in children treated with its gene therapy Zolgensma. In two of those cases, the company said testing showed evidence that the viral vector had integrated into patients' DNA; both children received treatment and continue to be monitored. The disclosure matters because vector integration and possible insertional oncogenesis are key long-term safety concerns for gene therapies, and the cases are likely to draw closer regulatory and clinical scrutiny.
Medicare has delayed until 2029 a controversial remote patient monitoring policy that would stop providers such as hospitals from using third parties to deliver those services, despite broad opposition. The decision matters because it postpones a major change for hospitals and RPM vendors while signaling that Medicare still intends to restrict third-party arrangements.
Medicare has delayed until 2029 a controversial proposal that would bar hospitals from using third-party vendors to deliver remote patient monitoring services. The agency moved ahead with the plan despite broad opposition, but the deferral gives critics more time to organize against it. For hospitals and RPM vendors, the decision leaves uncertainty over how remote monitoring programs can be structured and sustained.
The nonprofit biotech has in-licensed its first gene therapy and plans to expand its pipeline. It evaluates candidates based on unmet medical need, clinical evidence of safety and efficacy, and fit with institutional partners. Its funding model combines seed investment with commercial revenue and non-traditional sources, making the first license a signal that the accelerator’s approach is moving into execution and could support more rare-disease therapies.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
Artiva Biotherapeutics has discontinued development of its allogeneic natural killer cell therapy after two patients died in a clinical trial. The halt highlights the safety and risk-management challenges facing off-the-shelf cell therapies, particularly in autoimmune disease settings. Separately, Bristol Myers Squibb reported encouraging Phase I data for Zola-cel, showing continued momentum in cell therapy development despite such setbacks.